Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications

Front Immunol. 2022 Sep 16:13:998952. doi: 10.3389/fimmu.2022.998952. eCollection 2022.

Abstract

Long-time ischemia worsening transplant outcomes in vascularized composite allotransplantation (VCA) is often neglected. Ischemia-reperfusion injury (IRI) is an inevitable event that follows reperfusion after a period of cold static storage. The pathophysiological mechanism activates local inflammation, which is a barrier to allograft long-term immune tolerance. The previous publications have not clearly described the relationship between the tissue damage and ischemia time, nor the rejection grade. In this review, we found that the rejection episodes and rejection grade are usually related to the ischemia time, both in clinical and experimental aspects. Moreover, we summarized the potential therapeutic measures to mitigate the ischemia-reperfusion injury. Compare to static preservation, machine perfusion is a promising method that can keep VCA tissue viability and extend preservation time, which is especially beneficial for the expansion of the donor pool and better MHC-matching.

Keywords: adaptive immunity; innate immunity; ischemia-reperfusion injury (IRI); tissue damage; transplant rejection; vascularized composite allotransplantation (VCA).

Publication types

  • Review

MeSH terms

  • Humans
  • Perfusion / methods
  • Reperfusion Injury* / etiology
  • Transplantation Tolerance
  • Transplantation, Homologous
  • Vascularized Composite Allotransplantation* / adverse effects
  • Vascularized Composite Allotransplantation* / methods